Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi to expand French vaccine manufacturing site

Sanofi to expand French vaccine manufacturing site

12th October 2017

Sanofi has announced plans to expand its vaccine manufacturing site in Val de Reuil, France, in order to improve its supply of seasonal flu vaccines.

The 170 million euro (152.39 million pounds) investment will allow the company's vaccines business Sanofi Pasteurto ramp up production of its product VaxigripTetra to supply up to 70 countries across six continents.

Once completed, the revamped Val de Reuil facility will be the only site of its kind in France, with Sanofi Pasteur remaining the sole influenza vaccine producer in the country. Expansion work is expected to be completed by 2021, subject to relevant approvals, with the production of vaccines at the facility to commence in 2022.

Philippe Luscan, executive vice-president for global industrial affairs at Sanofi, said: "Our investment underlines Sanofi's intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets."

VaxigripTetra is a new quadrivalent influenza vaccine containing two A strains and two B strains of influenza, in line with World Health Organization recommendations.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.